Empirical Financial Services LLC d.b.a. Empirical Wealth Management Raises Position in ICU Medical, Inc. $ICUI

Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 22.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,875 shares of the medical instruments supplier’s stock after acquiring an additional 1,431 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in ICU Medical were worth $1,041,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Ameriprise Financial Inc. increased its holdings in ICU Medical by 18.5% during the 1st quarter. Ameriprise Financial Inc. now owns 693,711 shares of the medical instruments supplier’s stock worth $96,326,000 after purchasing an additional 108,493 shares during the period. Invesco Ltd. raised its holdings in ICU Medical by 80.1% in the first quarter. Invesco Ltd. now owns 203,827 shares of the medical instruments supplier’s stock valued at $28,303,000 after acquiring an additional 90,674 shares in the last quarter. Woodline Partners LP raised its holdings in ICU Medical by 31.6% in the first quarter. Woodline Partners LP now owns 160,910 shares of the medical instruments supplier’s stock valued at $22,344,000 after acquiring an additional 38,671 shares in the last quarter. Victory Capital Management Inc. lifted its stake in ICU Medical by 5.7% in the first quarter. Victory Capital Management Inc. now owns 149,246 shares of the medical instruments supplier’s stock worth $20,724,000 after acquiring an additional 8,101 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in ICU Medical by 3.0% during the 1st quarter. Principal Financial Group Inc. now owns 136,009 shares of the medical instruments supplier’s stock worth $18,886,000 after acquiring an additional 3,910 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other ICU Medical news, Director David C. Greenberg bought 1,200 shares of the company’s stock in a transaction on Wednesday, August 27th. The shares were bought at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the transaction, the director owned 7,960 shares of the company’s stock, valued at approximately $1,006,303.20. This trade represents a 17.75% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Vivek Jain bought 21,929 shares of the business’s stock in a transaction dated Thursday, August 14th. The shares were acquired at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the purchase, the chief executive officer owned 130,149 shares in the company, valued at approximately $14,686,013.16. This represents a 20.26% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.50% of the company’s stock.

ICU Medical Price Performance

ICU Medical stock opened at $122.07 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. The business has a 50 day simple moving average of $125.22 and a 200-day simple moving average of $131.87. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $196.26. The stock has a market capitalization of $3.01 billion, a PE ratio of -80.31 and a beta of 0.83.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company had revenue of $543.57 million for the quarter, compared to analysts’ expectations of $543.33 million. During the same period in the previous year, the company posted $1.56 EPS. ICU Medical’s revenue was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Raymond James Financial decreased their price objective on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a report on Saturday, September 27th. Piper Sandler upped their price objective on ICU Medical from $145.00 to $153.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Finally, Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $181.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.